Effects of a MAO-B inhibitor in the treatment of Alzheimer disease.

Abstract

119 patients were enrolled in a double-blind randomized parallel study versus placebo carried out to assess both the efficacy and tolerability of L-deprenyl (10 mg/day) for treatment of patients with organic mental disorders of the Alzheimer type (DAT). The treatments were given for 3 months, starting after a run-in period of 15 days to evaluate efficacy. A complete neuropsychological battery was administered monthly after the start of treatment whereas tolerability was assessed by checking, recording and classifying all the unfavorable experiences occurring. According to the results, L-deprenyl would seem to be a useful and reliable tool for the treatment of DAT patients in an attempt to improve their cognitive functions and reduce behavioral alterations, without frequent or severe side effects.

• Authors: A Mangoni, M P Grassi, L Frattola, R Piolti, S Bassi, A Motta, A Marcone, S Smirne
• Journal: European neurology (Eur Neurol) Vol. 31 Issue 2 Pg. 100-7 ( 1991) ISSN: 0014-3022 [Print] Switzerland
• PMID: 1904354 (Publication Type: Clinical Trial, Journal Article, Randomized Controlled Trial)

Chemical References

• Selegiline

Topics

• Activities of Daily Living
• Aged
• Alzheimer Disease (drug therapy)
• Double-Blind Method
• Humans
• Male
• Middle Aged
• Neuropsychological Tests
• Prognosis
• Selegiline (adverse effects, therapeutic use)